Abbott Laboratories (ABT) is back in focus after its fourth quarter 2025 earnings, where revenue of US$11.46b missed Wall ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the ...

Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table encapsulates their recent ratings, offering a ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results tomorrow before the ...

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.